The Week

Elevance Health (ELV) rose 3.31% this week to close at $407.50, beating the S&P 500’s 0.09% gain by about 3.22 percentage points. The move was back-loaded: Monday slipped toward the week’s low at $390.799, then the stock advanced for three straight sessions and touched a high of $416.58 on Thursday before easing Friday to finish above $407. Daily volume averaged roughly 1.11 million shares, slightly below the 60-day median. The week’s range was 6.54%.

Key Events

Company-specific announcements were light this week. On Tuesday, Guardant Health’s Shield blood test was reported to be covered by Carelon Health Services for colorectal cancer screening, a product-line extension within Elevance’s health services arm. The rest of the news flow was backward-looking: one piece compared Elevance’s stock performance with other health providers, while another noted the shares were still seen as undervalued after a roughly 37% run. A pre-market note on 2 September flagged the stock pulling back above its moving averages. Overall, the week’s information tilted toward valuation and relative performance, not fresh catalysts.

Analyst Ratings

Across 22 covering institutions, 12 rate the stock buy, 3 rate it over, and 7 rate it hold; none rate it under, sell, or no opinion. The consensus recommendation is buy. The consensus target price of $449.09524 sits about 10.21% above the $407.50 weekly close. Targets run from $393 to $492, with the low end below spot, highlighting meaningful dispersion. The stock ranks 3rd out of 9 names in its managed care industry; the industry average is 18 covering institutions.

The Week Ahead

The macro calendar is concentrated on 10 September, with weekly jobless claims, PPI readings, existing home sales, and the 10-year Treasury auction all due. For a health services and insurance name like ELV, PPI and jobless claims may offer marginal signals on labour costs and demand. There are no company-specific earnings or major events on the calendar yet, so the focus shifts back to how the broader rate and market environment affects valuation-sensitive names.

In Short

ELV outperformed the S&P 500 by about 3.22 percentage points this week, but volume sat slightly below the 60-day median, suggesting the move was more about valuation repair and relative performance than a cluster of company-specific catalysts. The sell side leans positive, with a consensus target about 10.21% above spot; the wide target range, though, reflects disagreement on earnings and policy sensitivity. What comes next depends on how macro data shifts rates and risk appetite, and whether the company generates new business-level news.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.